Have you or your loved ones been diagnosed with carcinoma, transitional cell?

You may be eligible to participate in a carcinoma, transitional cell clinical trial.

Have you or your loved ones been diagnosed with carcinoma, transitional cell? You may be eligible to participate in a carcinoma, transitional cell clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Carcinoma, Transitional Cell Clinical Trial in Charlotte NC
NCT03288545 | Phase 1 phase 2 | Interventional

Have you or your loved ones been diagnosed with carcinoma, transitional cell?

You may be eligible to participate in a carcinoma, transitional cell clinical trial.

Have you or your loved ones been diagnosed with carcinoma, transitional cell? You may be eligible to participate in a carcinoma, transitional cell clinical trial.

Active not recruiting

Male & Female

18 Years +

This study has recruited 348 Participants

This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of the study will look at locally advanced or metastatic urothelial cancer (la/mUC), which means the cancer has spread to nearby tissues or to other areas of the body. Other parts of the study will look at muscle-invasive bladder cancer (MIBC), which is cancer at an earlier stage that has spread into the muscle wall of the bladder. This study will look at the side effects of enfortumab vedotin alone and with other anticancer therapies. A side effect is a response to a drug that is not part of the treatment effect. This study will also test if the cancer shrinks with the different treatment combinations.